Skip to content
Screener

AngioDynamics ANGO Med Device — Gross Profit

Other segment segments

Med Tech
$23.29M+18.9%

Similar metrics at other companies

Roku, Inc. logo
ROKUDevices — Gross Profit
$26.94M+149,789%
InfuSystem Holdings logo
INFUDevice Solutions — Gross Profit
$5.36M-10.4%
Roku, Inc. logo
ROKUDevices — Gross Profit
$26.94M+149,789%
AeroVironment logo
AVAVService — Gross Profit
$20.95M+371%
Beta Technologies logo
BETAService — Gross Profit
$5.47M-7.5%
Fortinet logo
FTNTService — Gross Profit
$1.1B+13.6%

Other financials

Income statement

See full
Revenue$86.6M+8.0%
Gross profit$46.8M+10.8%
Operating income-$10.2M-76.1%
Net income-$11.4M-88.5%
EPS (diluted)-$0.27-80.0%

Balance sheet

See full
Cash & equivalents$53.9M-3.6%
Total debt$11.0M+8.0%
Total equity$170.8M-6.6%
Total assets$267.2M-4.6%

Cash flow

See full
Operating cash flow$17.5M
CapEx$413.0K-46.8%
Free cash flow$17.0M

Valuation

See full
Market cap$648.51M+88.9%
Enterprise value$605.6M+103%
P/S+0.9×

Profitability

See full
Gross margin54.6%+0.7pp
Operating margin-12.5%-1.0pp
Net margin-11.5%-0.1pp
FCF margin0.2%

Returns & leverage

See full
Return on equity-20.8%+4.8pp
Debt / equity0.1×0.0×
Current ratio2.2×0.0×

Where this comes from

Reported directly by AngioDynamics in its filing.

Tagged under the XBRL concept us-gaap:GrossProfit.

The source filing: AngioDynamics’s 10-K, filed July 14, 2026.

Filed
Jul 14, 2026, 3:42 PM EDT
Fiscal year
FY2026
Accession
0001628280-26-048138
Line itemYear ended May 31, 2026Year ended May 31, 2025Year ended May 31, 2024
Net sales$320,174$292,498$303,914
Cost of sales (exclusive of intangible amortization)145,282134,793149,216
Gross margin174,892157,705154,698
Operating expenses
Research and development29,44726,22231,512
Sales and marketing113,401103,135102,818
General and administrative43,69142,09241,164
Amortization of intangibles10,68210,31813,048

Item 15. Exhibits, Financial Statement Schedules.

FAQ

What is AngioDynamics's med device — gross profit?
AngioDynamics (ANGO) reported med device — gross profit of $19.92M in Q1 2026.
How has AngioDynamics's med device — gross profit changed year-over-year?
AngioDynamics's med device — gross profit decreased by 5.6% year-over-year, from $21.1M to $19.92M.
What is the long-term trend for AngioDynamics's med device — gross profit?
Over 4 years (2022 to 2026), AngioDynamics's med device — gross profit has grown at a -8.4% compound annual growth rate (CAGR), from $113.15M to $79.54M.
What does med device — gross profit mean?
Gross profit for the medical device segment is calculated as net sales minus the direct costs associated with producing and delivering those devices. It serves as a primary indicator of the segment's ability to generate profit from its core manufacturing and sales activities before accounting for operating expenses. A healthy gross profit is essential for covering R&D and administrative costs required to sustain the business.

Ask your AI about AngioDynamics's med device — gross profit.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude